TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: subjective distress after craniotomy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cytogenetic Complete Response (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of dental restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic impact of myocardial condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Creatinine-normalized u-LTE4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Dry Eye Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma AUCinf for PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax for PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Acne Vulgaris Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AMP hyperresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stability of angle fracture fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to 33 hours post dose (AUC0-33h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity post dose (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Correct diagnosis of mediastinal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau,ss of D930
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of D930
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum triglycerides level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systemic immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mucosal immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative incidence of death from vascular origin and other thrombotic and hemorrhagic events
Endpoint domain: Mortality/survival
Primary endpoint: Patient rated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with at least a 75 percent improvement in PASI score at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of subjects with at least a 75 percent improvement in PASI score at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Blood glucose measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Gamma Analysis Passing Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treadmill Endurance Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended Phase 2 Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Daily Urine Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes of Neurological Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Total Exercise Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who Complete the 66-Day Structured Daily Diary
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Completion of 66-Day Structured Daily Diary by Modality Type
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reasons and Rate of for Non-completion of 66-Day Structured Daily Diary
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in ADHD-RS-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticosteroid insufficiency in critical illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessment/self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Falls
Endpoint domain: Adverse events/effects
Primary endpoint: improvement of spontaneous bowel movements (SBMs) per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfaction with bowel function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients Who Experience Transplant Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Complete Molecular Response (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone mineral density at the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing adverse events or serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Failures of the device and persons using the device
Endpoint domain: Adverse events/effects
Primary endpoint: Injury, harm or medically relevant discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Time in hypotension (MAP <72 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: joint bleeding episodes per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First confirmed crossing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ACLF
Endpoint domain: Mortality/survival
Primary endpoint: Nasal polyps Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of Creatine Kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Corneal Staining Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid craving scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apparent Terminal Elimination Half-life (T½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successful orotracheal intubation at first laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinically Significant Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cervical ripening efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean Duration of Grade 4 Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: preoperative cervical width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic and local safety assessed by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative 2nd Day CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value (NPV) of MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma and bronchoalveolar lavage fluid concentrations of linezolid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients able to tolerate all study procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Dyskinesia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time to heal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Premature birth
Endpoint domain: Mortality/survival
Primary endpoint: Function of shoulder joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: insertion time of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: nasotracheal intubation time with the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total nasotracheal intubation time with the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total number of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pediatric Symptoms Checklist (PSC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chronic venous insufficiency (CVI) evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Detection of unilateral hemispheric EEG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Asthma Worsening Events
Endpoint domain: Adverse events/effects
Primary endpoint: Model prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inferior Corneal Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Symptom Based on Diary Data
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum voluntary ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 min walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT-G questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Instant spinal correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-month spinal control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With In Vitro Dasatinib Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain as Measured by Subjective Pain Intensity Rating (SPIR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drinks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMI and all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Brain MRI with and without contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in K-SARA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mental Health Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DNA analysis of discarded media drops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in Binding potential (BPnd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drinks Per Drinking Day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Level of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endothelial function with FMD variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uveal melanoma-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Impact of the diagnosis and treatment of uveal melanoma on mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Days from biopsy to start of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tooth color and whiteness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short term outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral shedding rate change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: change in mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Seizure Frequency Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6-months treatment-related grade 3-4 toxicity event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of hyperventilation syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants With HBV DNA <400 Copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: L-arginine-NO biosynthesis pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: internal fit evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: technical success rate of PTA procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety as measured by local and systemic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Proliferation arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polyploidization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of episodes of acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nocturnal Systolic Blood Pressure Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensitivity and specificity of echographic measurement of ONSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expression of PD-(L)-1 receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Replacement of Tissue Expander With Permanent Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absolute and percent change from baseline in plasma triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute and percent change from baseline in plasma low density lipoprotein-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lung diffusion capacity for carbon monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevention of Retinopathy of Prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of Palmoplantar pustulosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of Generalized pustular psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Amount of singlet oxygen generated by the left forearm skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity in the Target Joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative Stress Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in walking speed during a 6-minutes walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the size of the pulmonary nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes of the forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Nfit score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-Neglect Severity Scale (SSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of urinary excretion of magnesium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Period to thick smear positivity after challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parasitemia and kinetics of parasitemia as measured by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of signs or symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Indocyanine Green accumulation in forearm muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle T2 elevation in forearm muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average percentage of ACL tibial footprint coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health and Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Normal Blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Behavioral aspects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pain Intensity Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Voice Handicap Index-10 (VHI-10) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-operation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Cognitive test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-Report Receipt of HIV and Hepatitis C Test Results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pelvic Organ Prolapse Quantification (POP-Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical interventions during delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Use of birth analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sleep onset Latency (SOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Sleep time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OxAFQ-C
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: OxAFQ-P
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to 24-week Confirmed EDSS Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to 48-week Confirmed EDSS Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to 24-week Confirmed EDSS Improvement Where Baseline ≥ 2.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Collateral flow index (CFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed complications
Endpoint domain: Adverse events/effects
Primary endpoint: Effect size of accuracy in probability revisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial glycocalyx thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of serum Parathyroid Hormone (PTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Kidney Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ECLS withdrawal failure
Endpoint domain: Adverse events/effects